FDC Reports Launches PharmAsia

FDC Reports, the world’s leading information source on the pharma sector has now launched PharmAsiaNews.com, to capture all the exciting pharma news from India, China and Japan.

Those have read the “Pink Sheet” will know that FDC Reports is renowned for exceptionally accurate, objective and insightful stories on the pharma sector. With FDC now turning its attention to the exciting pharma developments in India, we (those of us who thirst for this sort of knowledge) are in for a treat. For access this subscription based service, please click here. Below is the press release:

F-D-C Reports, Inc. Launches PharmAsiaNews.com

F-D-C Reports, Inc. announces the launch of PharmAsiaNews.com: a new subscription-based online service covering Rx drugs, biologics and devices in China, India, Japan and other nations in the Pacific Rim.

“By leveraging the editorial excellence of ‘The Pink Sheet,’ the leading information source for
U.S. pharmaceutical industry information since 1939 into the Asian markets and combining it
with new features enabled by Web 2.0 technology, we believe PharmAsiaNews.com will
become an important information service to multinational pharmaceutical companies who are
making increasingly larger bets in the region,” said Gerry Stoia, V.P. of Elsevier Health Science
Division’s Pharma Solutions unit and President of F-D-C Reports, Inc.

“Increasingly over the past several years, customers have requested reliable, independent and
accurate ‘Pink Sheet like’ coverage of business and regulatory developments in the APAC
region. F-D-C Reports, Inc. has answered the call for information on developments in China,
India, Japan and other countries in the region via our PharmAsiaNews.com service,” Stoia

The result is a publication that provides readers with the broadest spectrum of news sources,
including: original on-the-ground reporting from news bureaus across Asia; guest columns;
exclusive interviews; news summaries; English translation summaries of Chinese- and
Japanese-language news; and aggregated content from around the globe.

“What makes PharmAsiaNews.com unique is our commitment to original local market coverage and insights developed by local staff who are resident in the market. This is not a service that provides solely rewritten press releases and translated local language stories. By leveraging Elsevier’s global footprint, we’ve brought local talent aboard to provide our customers with the ‘boots on the ground’ coverage our customers have requested,” said Joe Hecker, Editor-in-Chief at Elsevier’s F-D-C Reports, Inc.

Subscribers to PharmAsiaNews.com get online access to around-the-clock coverage of the
rapidly expanding Asia marketplace, including China, India, Japan and other nations in the
Pacific Rim; twice-weekly email updates; full archive access; breaking news alerts; and other
online resources.

For more information please visit www.pharmasianews.com or contact Sean Smith at
[email protected] or call 1-240-221-4535.

About F-D-C Reports
F-D-C Reports, Inc. provides up-to-date information about the worldwidehealth care industry via its publications including “The Pink Sheet”®, “The Gray Sheet”®, “The Rose Sheet”®, “The Tan Sheet”®, and Pharmaceutical Approvals Monthly. The publications are read extensively by pharmaceutical and healthcare executives, policy-makers, and analysts seeking to understand the developments affecting the U.S. regulation and marketing of healthcare products and services. F-D-C Reports, Inc. has one of the largest, most experienced, and most respected editorial teams reporting on the latest regulatory, legislative, and business news affecting the U.S. drug, biotechnology, medical device, nonprescription drug, nutritionals, and cosmetics industries. F-D-C Reports, Inc. is part of Elsevier.

Shamnad Basheer

Shamnad Basheer

Prof. (Dr.) Shamnad Basheer founded SpicyIP in 2005. He's also the Founder of IDIA, a project to train underprivileged students for admissions to the leading law schools. He served for two years as an expert on the IP global advisory council (GAC) of the World Economic Forum (WEF). In 2015, he received the Infosys Prize in Humanities in 2015 for his work on legal education and on democratising the discourse around intellectual property law and policy. The jury was headed by Nobel laureate, Prof. Amartya Sen. Professional History: After graduating from the NLS, Bangalore Prof. Basheer joined Anand and Anand, one of India’s leading IP firms. He went on to head their telecommunication and technology practice and was rated by the IFLR as a leading technology lawyer. He left for the University of Oxford to pursue post-graduate studies, completing the BCL, MPhil and DPhil as a Wellcome Trust scholar. His first academic appointment was at the George Washington University Law School, where he served as the Frank H Marks Visiting Associate Professor of IP Law. He then relocated to India in 2008 to take up the MHRD Chaired Professorship in IP Law at WB NUJS, a leading Indian law school. Later, he was the Honorary Research Chair of IP Law at Nirma University and also a visiting professor of law at the National Law School (NLS), Bangalore. Prof. Basheer has published widely and his articles have won awards, including those instituted by ATRIP, the Stanford Technology Law Review and CREATe. He was consulted widely by the government, industry, international organisations and civil society on a variety of IP issues. He also served on several government committees.

Leave a Reply

Your email address will not be published.